Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 1/2011

01-02-2011

New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I

Authors: Bill Giannakopoulos, Peyman Mirarabshahi, Steven A. Krilis

Published in: Current Rheumatology Reports | Issue 1/2011

Login to get access

Abstract

β2-glycoprotein I (β2GPI) is the major autoantigen in the antiphospholipid syndrome. The central importance of understanding β2GPI physiology from the perspective of the rheumatologist is that it forms the foundation for understanding the pathophysiology underlying autoantibody generation, and the diverse mechanisms by which anti-β2GPI antibodies in complex with β2GPI may predispose an individual to the antiphospholipid syndrome clinical phenotype. This review examines some of the latest novel findings in this area.
Literature
1.
McNeil, H.P., et al., Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A, 1990. 87: p. 4120–4.CrossRefPubMed
2.
Miyakis, S., et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost, 2006. 4(2): p. 295–306.CrossRefPubMed
3.
Meroni, P.L., et al., Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost, 2007. 5(12): p. 2421–8.CrossRefPubMed
4.
• Urbanus, R.T., et al., Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol, 2009. 8(11): p. 998–1005. This article emphasizes the fact that lupus anticoagulant is a significant risk factor for stroke in young women, especially in the context of other concurrent risk factors such as smoking.
5.
Jankowski, M., et al., Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood, 2003. 101: p. 157–62.CrossRefPubMed
6.
Giannakopoulos, B., et al., Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood, 2007. 109(2): p. 422–30.CrossRefPubMed
7.
Miyakis, S., B. Giannakopoulos, and S.A. Krilis, Beta 2 glycoprotein I—function in health and disease. Thromb Res, 2004. 114(5–6): p. 335–46.CrossRefPubMed
8.
Lozier, J., N. Takahashi, and F.W. Putnam, Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A, 1984. 81(12): p. 3640–4.CrossRefPubMed
9.
Kamboh, M.I., R.E. Ferrell, and B. Sepehrnia, Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (beta 2-glycoprotein I). Am J Hum Genet, 1988. 42(3): p. 452–7.PubMed
10.
Hunt, J.E., R.J. Simpson, and S.A. Krilis, Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A, 1993. 90(6): p. 2141–5.CrossRefPubMed
11.
Bouma, B., et al., Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J, 1999. 18(19): p. 5166–74.CrossRefPubMed
12.
Schwarzenbacher, R., et al., Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J, 1999. 18(22): p. 6228–39.CrossRefPubMed
13.
• Agar, C., et al., Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 2010. 116(8): p. 1336–43. This article demonstrates that β2GPI can exist in two conformations in vivo: a circular form and an open form. The major APS epitope on DI is cryptic in the circular form.
14.
Reddel, S.W., et al., Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun, 2000. 15: p. 91–6.CrossRefPubMed
15.
Oppermann, M., et al., The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol, 2006. 144(2): p. 342–52.CrossRefPubMed
16.
Chen, V.M. and P.J. Hogg, Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost, 2006. 4(12): p. 2533–41.CrossRefPubMed
17.
• Passam, F.H., et al., Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood, 2010. 116(11): p. 1995–7. This article reveals for the first time that β2GPI is a substrate of thiol oxidoreductases.
18.
Haendeler, J., et al., Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nature Cell Biology, 2002. 4(10): p. 743–749.CrossRefPubMed
19.
• Passam, F.H., et al., Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost, 2010. 8: p. 1754–1762. This article describes for the first time the importance of TRX-1 in regulating the β2GPI–vWF interaction and the implications of this for platelet adhesion to vWF. It also raises the issue that all functional studies of β2GPI need to be interpreted in the context of the redox status of β2GPI.
20.
Hulstein, J.J., et al., beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood, 2007. 110(5): p. 1483–91.CrossRefPubMed
21.
• Ioannou, Y., et al., Naturally occurring free thiols within {beta}2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood, 2010. 116(11): p. 1961–70. This article reveals that β2GPI can exist in a reduced form in vivo and that it serves an important biological function in this form, protecting endothelial cells against oxidative stress injury.
22.
Lin, K.Y., et al., beta(2)-glycoprotein I protects J774A.1 macrophages and human coronary artery smooth muscle cells against apoptosis. J Cell Biochem, 2005. 94(3): p. 485–96.CrossRefPubMed
23.
Lin, K.Y., et al., Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci, 2001. 69(6): p. 707–19.CrossRefPubMed
24.
Averna, M., et al., Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. Int J Biochem Cell Biol, 2004. 36(7): p. 1297–305.CrossRefPubMed
25.
Cai, G., T. Satoh, and H. Hoshi, Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum. Biochim Biophys Acta, 1995. 1269(1): p. 13–8.CrossRefPubMed
26.
Kutala, V.K., et al., Role of oxygen in postischemic myocardial injury. Antioxid Redox Signal, 2007. 9(8): p. 1193–206.CrossRefPubMed
27.
Ravichandran, K.S. and U. Lorenz, Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol, 2007. 7(12): p. 964–74.CrossRefPubMed
28.
Casciola-Rosen, L.A., G. Anhalt, and A. Rosen, Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med, 1994. 179: p. 1317–30.CrossRefPubMed
29.
Balasubramanian, K., J. Chandra, and A.J. Schroit, Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem, 1997. 272(49): p. 31113–7.CrossRefPubMed
30.
Manfredi, A.A., et al., Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum, 1998. 41(2): p. 215–23.CrossRefPubMed
31.
Balasubramanian, K., S.N. Maiti, and A.J. Schroit, Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis, 2005. 10(2): p. 439–46.CrossRefPubMed
32.
Sheng, Y., et al., Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem, 2001. 276(17): p. 13817–21.PubMed
33.
Maiti, S.N., et al., Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells: Binding to LRP receptor family members. J Biol Chem, 2007.
34.
Bevers, E.M., et al., Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets. Biochem J, 2005. 386(Pt 2): p. 271–9.PubMed
35.
• Reed, J.H., et al., Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum, 2009. 60(3): p. 860–9. This was the first study to reveal that Ro60 on apoptotic cells rather than phosphatidylserine functions as a key receptor for β2GPI.
36.
Clancy, R.M., When the Levee Doesn’t Break: A Novel Role of beta(2)-Glycoprotein I to Protect Against Congenital Heart Block. Arthritis and Rheumatism, 2009. 60(3): p. 636–638.CrossRefPubMed
37.
Levine, J.S., et al., Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol, 2006. 177(9): p. 6504–16.PubMed
38.
Mevorach, D., et al., Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med, 1998. 188(2): p. 387–92.CrossRefPubMed
39.
Georgiev, M., et al., Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum, 2005. 52(1): p. 225–38.CrossRefPubMed
40.
Arbuckle, M.R., et al., Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med, 2003. 349(16): p. 1526–33.CrossRefPubMed
41.
Buttari, B., et al., Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type I response. Blood, 2005. 106: p. 3880–7.CrossRefPubMed
42.
Morgan, P.E., A.D. Sturgess, and M.J. Davies, Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum, 2005. 52(7): p. 2069–79.CrossRefPubMed
43.
Pritzker, L.B., et al., Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry, 2000. 39(18): p. 5382–8.CrossRefPubMed
44.
Marshak-Rothstein, A. and I.R. Rifkin, Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol, 2007. 25: p. 419–41.CrossRefPubMed
45.
Vollmer, J., et al., Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med, 2005. 202(11): p. 1575–85.CrossRefPubMed
46.
Hurst, J., et al., TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology, 2009. 214(8): p. 683–91.CrossRefPubMed
47.
Demaria, O., et al., TLR8 deficiency leads to autoimmunity in mice. J Clin Invest, 2010. 120(10): p. 3651–62.PubMed
Metadata
Title
New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I
Authors
Bill Giannakopoulos
Peyman Mirarabshahi
Steven A. Krilis
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0151-9

Other articles of this Issue 1/2011

Current Rheumatology Reports 1/2011 Go to the issue

ReviewPaper

Is Testing for Antiphosphatidylethanolamine Antibodies Clinically Useful?

ReviewPaper

Biomarkers of Scleroderma Lung Disease: Recent Progress

ReviewPaper

The Genetics of Scleroderma

ReviewPaper

Update on Antiphospholipid Syndrome in Children

ReviewPaper

Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand?

ReviewPaper

A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits